Vericel to Host Third-Quarter 2017 Earnings Webcast and Conference Call on November 7, 2017

CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call:

What:	Vericel Corporation Third-Quarter 2017 Earnings Call
When:	Tuesday, November 7, 2017 at 8:00am (EST)
Where:	http://investors.vcel.com/events.cfm
How:	The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events.cfm.  Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary.

To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation third-quarter 2017 investor conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173.

If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events.cfm until November 7, 2018. A replay of the call will also be available until 11:00am (EST) on November 11, 2017 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 7097908.

About Vericel CorporationVericel develops, manufactures, and markets expanded autologous cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.

Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2017 Vericel Corporation. All rights reserved.

Global Media Contacts:David SchullRusso Partners LLC+1 212-845-4271 (office)+1 858-717-2310 (mobile)[email protected]

Karen ChaseRusso Partners LLC+1 646-942-5627 (office)+1 917-547-0434 (mobile)[email protected]

Investor Contacts: Chad RubinThe Trout Group[email protected]+1 (646) 378-2947

Lee SternThe Trout Group[email protected]+1 (646) 378-2922

Source: Vericel Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• MidWestOne Financial Group, Inc. (MOFG) Misses Q1 EPS by 15c
• Arca Biopharma (ABIO) Reports Q1 Loss of $0.14